In a collaboration with a leading global pharmaceutical company, Volv Global applied machine learning to 24 million UK primary care records, surfacing approximately 1,200 likely-undiagnosed GEP-NET patients – and finding they are 5–7 years younger than those currently diagnosed. Approximately 1,200 UK patients have records consistent with undiagnosed GEP-NETs – roughly one additional patient